Antibody-Guided PROTAC Conjugate Blocks Tumor-Stroma Crosstalk by Silencing Extracellular Vesicles
- Researchers built Ctx-ETAC, a degrader-antibody conjugate pairing the approved EGFR antibody cetuximab with an engineered PROTAC payload, attached via a bioorthogonal reaction at a defined, controlled ratio per antibody.
- Its PROTAC payload pairs an indomethacin-derived COX-2 ligand with a VHL-recruiting peptide via a cathepsin B-cleavable linker, releasing the degrader selectively inside EGFR-positive tumor cells and activated fibroblasts.
- Degrading COX-2 in both cell types substantially curtails extracellular vesicle secretion, severing a key tumor-stroma signaling channel and nudging fibroblasts toward a quiescent, less tumor-supportive state.
- In a lung cancer xenograft model, Ctx-ETAC outperformed cetuximab alone in restraining tumor growth without added systemic toxicity, supporting microenvironment-targeted degradation as a therapeutic strategy.
Finally, a DAC that isn't just "ADC with a cooler payload" — swapping a cytotoxin for a VHL-PROTAC means efficacy doesn't hinge on brute-force poisoning of every internalized antibody; you get catalytic, event-driven target destruction instead. Smart target choice: COX-2 isn't the oncogenic driver, it's stromal plumbing. Cutting EV secretion to defuse tumor-fibroblast crosstalk instead of chasing EGFR resistance mutations directly is a genuinely different SAR logic than the usual "degrade the driver" playbook. Chemistry-wise, nothing exotic — indomethacin-COX-2 ligand, VHL peptide, cathepsin B-cleavable linker, defined-DAR bioorthogonal attachment. That's the point: boringly tractable, which is exactly what a translatable conjugation platform should look like. Real question is whether COX-2/EV silencing holds up in a fibroblast-rich, resistant tumor, not just a clean xenograft — but as a proof that microenvironment-directed degradation is maturing past a concept, this is convincing.